Kaken Pharmaceutical Co Stock Net Income
| KKPCF Stock | USD 23.65 0.00 0.00% |
Fundamental analysis of Kaken Pharmaceutical allows traders to better anticipate movements in Kaken Pharmaceutical's stock price by examining its financial health and performance throughout various phases of its business cycle.
Kaken |
Kaken Pharmaceutical Co Company Net Income Analysis
Kaken Pharmaceutical's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Kaken Pharmaceutical Net Income | 9.09 B |
Most of Kaken Pharmaceutical's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kaken Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Kaken Pharmaceutical Co reported net income of 9.09 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is significantly lower than that of the firm.
Kaken Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kaken Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kaken Pharmaceutical could also be used in its relative valuation, which is a method of valuing Kaken Pharmaceutical by comparing valuation metrics of similar companies.Kaken Pharmaceutical is currently under evaluation in net income category among its peers.
Kaken Fundamentals
| Return On Equity | 6.65 | |||
| Return On Asset | 6.36 | |||
| Profit Margin | 12.00 % | |||
| Operating Margin | 22.04 % | |||
| Current Valuation | (68.22 B) | |||
| Shares Outstanding | 37.47 M | |||
| Shares Owned By Insiders | 13.21 % | |||
| Shares Owned By Institutions | 32.63 % | |||
| Price To Earning | 16.87 X | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 75.78 B | |||
| Gross Profit | 41.58 B | |||
| EBITDA | 19.23 B | |||
| Net Income | 9.09 B | |||
| Cash And Equivalents | 73.7 B | |||
| Total Debt | 3.85 B | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 5.70 X | |||
| Cash Flow From Operations | 13.34 B | |||
| Earnings Per Share | 1.66 X | |||
| Number Of Employees | 1.16 K | |||
| Beta | 0.3 | |||
| Market Capitalization | 980.27 M | |||
| Last Dividend Paid | 1.15 |
About Kaken Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kaken Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kaken Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kaken Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Kaken Pink Sheet
Kaken Pharmaceutical financial ratios help investors to determine whether Kaken Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kaken with respect to the benefits of owning Kaken Pharmaceutical security.